Piramal Pharma Limited(IN:PPLPHARMA)
₹239.25-0.15 (-0.06%)
IN:PPLPHARMA
Piramal Pharma Limited financials statements
₹239.25
At close:-0.15 (-0.06%)
Want to see IN:PPLPHARMA full AI Analyst Report?
Piramal Pharma Limited (PPLPHARMA) Ratios
11 Followers
Piramal Pharma Limited Ratios
IN:PPLPHARMA's free cash flow for Q2 2027 was ₹0.00. For the 2027 fiscal year, IN:PPLPHARMA's free cash flow was increased by ₹0.00 and operating cash flow was ₹0.00. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.51 | 1.54 | 1.25 | 1.26 | 1.34 |
| Quick Ratio | 0.87 | 0.93 | 0.75 | 0.82 | 0.88 |
| Cash Ratio | 0.26 | 0.13 | 0.08 | 0.05 | 0.08 |
| Solvency Ratio | 0.05 | 0.12 | 0.10 | 0.06 | 0.16 |
| Operating Cash Flow Ratio | 0.29 | 0.24 | 0.23 | 0.13 | 0.25 |
| Short-Term Operating Cash Flow Coverage | 1.13 | 0.59 | 0.48 | 0.23 | 0.54 |
| Net Current Asset Value | ₹ -26.11B | ₹ -17.55B | ₹ -19.36B | ₹ -29.14B | ₹ -20.33B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.32 | 0.31 | 0.31 | 0.39 | 0.32 |
| Debt-to-Equity Ratio | 0.70 | 0.60 | 0.60 | 0.83 | 0.62 |
| Debt-to-Capital Ratio | 0.41 | 0.37 | 0.37 | 0.45 | 0.38 |
| Long-Term Debt-to-Capital Ratio | 0.35 | 0.28 | 0.24 | 0.33 | 0.28 |
| Financial Leverage Ratio | 2.20 | 1.93 | 1.94 | 2.14 | 1.91 |
| Debt Service Coverage Ratio | 0.54 | 0.69 | 0.48 | 0.32 | 0.71 |
| Interest Coverage Ratio | 0.27 | 1.61 | 1.16 | -0.10 | 1.88 |
| Debt to Market Cap | 0.31 | 0.16 | 0.28 | 0.68 | 0.18 |
| Interest Debt Per Share | 45.40 | 39.38 | 40.52 | 49.32 | 35.55 |
| Net Debt to EBITDA | 4.47 | 2.64 | 3.19 | 6.43 | 3.10 |
| Profitability Margins | |||||
| Gross Profit Margin | 26.87% | 60.58% | 60.08% | 15.51% | 21.04% |
| EBIT Margin | 1.86% | 9.19% | 7.66% | 2.40% | 10.27% |
| EBITDA Margin | 11.23% | 18.20% | 16.73% | 11.95% | 19.21% |
| Operating Profit Margin | 1.02% | 7.49% | 6.36% | -0.51% | 5.70% |
| Pretax Profit Margin | -1.99% | 4.58% | 2.19% | -1.70% | 7.39% |
| Net Profit Margin | -3.68% | 1.01% | 0.22% | -2.63% | 5.73% |
| Continuous Operations Profit Margin | -3.68% | 1.01% | 0.22% | -2.63% | 5.73% |
| Net Income Per EBT | 185.13% | 21.98% | 9.94% | 155.19% | 77.52% |
| EBT Per EBIT | -194.80% | 61.10% | 34.50% | 333.94% | 129.80% |
| Return on Assets (ROA) | -1.81% | 0.58% | 0.12% | -1.28% | 2.94% |
| Return on Equity (ROE) | -3.99% | 1.12% | 0.23% | -2.75% | 5.61% |
| Return on Capital Employed (ROCE) | 0.68% | 5.70% | 4.75% | -0.34% | 3.83% |
| Return on Invested Capital (ROIC) | 0.63% | 1.11% | 0.40% | -0.28% | 2.59% |
| Return on Tangible Assets | -2.36% | 0.79% | 0.16% | -1.85% | 4.44% |
| Earnings Yield | -1.80% | 0.30% | 0.11% | -2.30% | 1.66% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.11 | 3.86 | 3.80 | 3.90 | 3.59 |
| Payables Turnover | 2.62 | 2.33 | 2.13 | 5.02 | 5.05 |
| Inventory Turnover | 2.12 | 1.54 | 1.50 | 3.56 | 3.73 |
| Fixed Asset Turnover | 1.57 | 1.80 | 1.70 | 1.59 | 1.77 |
| Asset Turnover | 0.49 | 0.58 | 0.53 | 0.49 | 0.51 |
| Working Capital Turnover Ratio | 3.97 | 5.80 | 7.83 | 6.99 | 9.87 |
| Cash Conversion Cycle | 121.74 | 174.24 | 167.92 | 123.32 | 127.12 |
| Days of Sales Outstanding | 88.80 | 94.64 | 96.07 | 93.52 | 101.57 |
| Days of Inventory Outstanding | 172.46 | 236.31 | 243.49 | 102.57 | 97.88 |
| Days of Payables Outstanding | 139.52 | 156.72 | 171.64 | 72.76 | 72.34 |
| Operating Cycle | 261.26 | 330.96 | 339.56 | 196.08 | 199.45 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 10.56 | 6.66 | 7.89 | 3.99 | 6.30 |
| Free Cash Flow Per Share | 3.85 | 1.70 | 2.30 | -3.97 | -1.01 |
| Dividend Paid and CapEx Coverage Ratio | 1.54 | 1.31 | 1.41 | 0.47 | 0.82 |
| Capital Expenditure Coverage Ratio | 1.57 | 1.34 | 1.41 | 0.50 | 0.86 |
| Operating Cash Flow Coverage Ratio | 0.25 | 0.18 | 0.21 | 0.09 | 0.19 |
| Operating Cash Flow to Sales Ratio | 0.16 | 0.10 | 0.12 | 0.07 | 0.12 |
| Free Cash Flow Yield | 2.82% | 0.75% | 1.77% | -5.93% | -0.55% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -55.50 | 326.86 | 927.86 | -43.48 | 60.06 |
| Price-to-Sales (P/S) Ratio | 2.04 | 3.34 | 2.02 | 1.14 | 3.44 |
| Price-to-Book (P/B) Ratio | 2.22 | 3.72 | 2.09 | 1.20 | 3.37 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 35.50 | 132.61 | 56.53 | -16.86 | -183.45 |
| Price-to-Operating Cash Flow Ratio | 12.93 | 33.87 | 16.46 | 16.75 | 29.46 |
| Price-to-Earnings Growth (PEG) Ratio | 0.12 | 0.83 | -8.51 | 0.29 | -1.78 |
| Enterprise Value Multiple | 22.63 | 20.97 | 15.28 | 16.01 | 21.02 |
| Enterprise Value | 225.42B | 345.79B | 208.88B | 135.48B | 264.81B |
| EV to EBITDA | 22.63 | 20.97 | 15.28 | 16.01 | 21.02 |
| EV to Sales | 2.54 | 3.82 | 2.56 | 1.91 | 4.04 |
| EV to Free Cash Flow | 44.24 | 151.72 | 71.41 | -28.17 | -215.13 |
| EV to Operating Cash Flow | 16.11 | 38.75 | 20.79 | 28.00 | 34.55 |
| Tangible Book Value Per Share | 30.35 | 30.14 | 28.45 | 19.20 | 19.40 |
| Shareholders’ Equity Per Share | 61.61 | 60.63 | 62.15 | 55.86 | 55.03 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.85 | 0.78 | 0.90 | -0.55 | 0.22 |
| Revenue Per Share | 66.94 | 67.61 | 64.20 | 58.40 | 53.90 |
| Net Income Per Share | -2.46 | 0.68 | 0.14 | -1.54 | 3.09 |
| Tax Burden | 1.85 | 0.22 | 0.10 | 1.55 | 0.78 |
| Interest Burden | -1.07 | 0.50 | 0.29 | -0.71 | 0.72 |
| Research & Development to Revenue | 0.00 | 0.01 | 0.01 | 0.01 | 0.02 |
| SG&A to Revenue | 0.26 | 0.28 | 0.03 | 0.03 | 0.03 |
| Stock-Based Compensation to Revenue | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
| Income Quality | -4.29 | 9.79 | 56.37 | -3.01 | 1.76 |
Currency in INR

